Skip to content

Effect of Oral Pentoxifyllin on Spermogram

Effect Of Oral Pentoxifyllin On Spermogram In Olygoastenosperm Men

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201009094721N1
Enrollment
61
Registered
2010-09-26
Start date
2001-09-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Male infertility. Male infertility, Oligospermia NOS

Interventions

Intervention: oral pentoxifylin Dosage, 400 mg 3 times a day, for 3 months, oraly.
Treatment - Drugs
Intervention: oral pentoxifylin Dosage, 400 mg 3 times a day, for 3 months, oraly

Sponsors

Tabriz University Of Medical Scienses
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Men with primary infertility, having analysis of sperm before treatment, presence of olygoastenospermia Exclusion Criteria: Contraindication of pentoxyfilin, Other medical diseases (diabetes, hypertension, …), any drug consumption

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Motility of sperm. Timepoint: before treatment and 3 monthes aftter treatments. Method of measurement: Percentage of sperms with mobile flagel.;Volume of semen. Timepoint: 3 months. Method of measurement: volume of semen in ml.;Morphology of sperm. Timepoint: before treatment and 3 monthes after treatment. Method of measurement: labratory survey: 60% of sperms with normal morphology and lower than 3% immature form.;Total nomber of sperms. Timepoint: before treatments and 3 months after treatment. Method of measurement: count of total sperm in microscopic field.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactD. Kamaladdin Hassanzadeh

Tabriz university Of Medical Scienses

drhassanzadehka@yahoop_k_hn@yahoo.com+98 41 1477 1622

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026